IGNITING THE EMBERS OF HOPE

SMALL MOLECULE IMMUNOTHERAPIES

ROSE BENGAL MEDICAL SCIENCE

INVESTOR PRESENTATION / 2026

OTCQB: PVCT

FORWARD-LOOKING STATEMENTS

The information in this presentation may include “forward-looking

statements” within the meaning of U.S. federal securities legislation

and relating to the business of Provectus Biopharmaceuticals, Inc.

and its affiliates (Provectus or the Company) that are based on the

opinions and estimates of Company management and are subject

to a variety of risks, uncertainties, and other factors, which could

cause actual events or results to differ materially from those

projected in these forward-looking statements.

Forward-looking statements are often, but not always, identified

using words such as “seek,” “anticipate,” “budget,” “plan,”

“continue,” “estimate,” “expect,” “forecast,” “may,” “will,” “project,”

“predict,” “potential,” “targeting,” “intend,” “could,” “might,”

“should,” “believe,” and similar words suggesting future outcomes

or statements regarding an outlook.

The safety, efficacy, and durability of agents and/or uses under

investigation by Provectus have not been established. There is no

guarantee these agents will receive health authority approval or

become commercially available in any country or such agents as

products will achieve any revenue levels.

Due to the risks, uncertainties, and assumptions inherent in

forward-looking statements, readers should not place undue

reliance on them. Forward-looking statements contained in this

presentation are made as of the date hereof or as of the date

specifically specified herein.

The Company undertakes no obligation to update or revise any

forward-looking statements, whether because of new information,

future events, or otherwise, except in accordance with applicable

federal securities laws. Forward-looking statements are expressly

qualified by this cautionary statement.

Risks, uncertainties, and assumptions include those discussed in

the Company’s filings with the U.S. Securities and Exchange

Commission, including those described in Item 1A of Provectus’s:

• Annual Report on Form 10-K for the period ended

December 31, 2024, and

• Quarterly Report on Form 10-Q for the period ended

September 31, 2025.

OTCQB: PVCT

THE ROSE BENGAL

SODIUM (RBS)

MOLECULE

OTCQB: PVCT

EXECUTIVE SUMMARY

Provectus Biopharmaceuticals (OTCQB: PVCT) is a clinical-stage

biotechnology company with a bioactive small molecule platform of

immunotherapy drug candidates and formulations.

Socioeconomic Benefits of Better Healthcare

Better, accessible, and affordable healthcare can boost lives and

productivity, and increase income and GDP, contributing to more

robust economies for everyone.

We are confident Provectus’s RBS medical science can lead to life-

changing advancements in immunotherapy treatments for cancer

and many other diseases.

Our commitment lies in alleviating the burden of illness free from

undue emotional, financial, and other strains on patients, while

ensuring sustained value for Provectus shareholders.

Access to leading healthcare should never hinge on socioeconomic

status or geographic location. This principle underscores our

profound responsibility to the global public trust we uphold.

OTCQB: PVCT

EXECUTIVE SUMMARY (continued)

RBS Medical Science

Innovation, versatility, and consistency drive clinical and

financial value compared to standard of care medicines. RBS

small molecule immunotherapies may have the potential to

improve quality of life, resolve disease, enhance survival, and

work synergistically with other treatments.

Injectable Solid Tumor Oncology

Pursuing clinical, regulatory, and commercial milestone

achievements for lead intratumoral cancer immunotherapy

PV-10 and lead indication metastatic pancreatic cancer.

Potential PV-10 treatments target total patient populations

of more than $125+ billion in annual sales.

Added Platform Value

RBS medical science also supports clinical-stage

immunotherapy drug candidates in dermatology (top.) and

ophthalmology (top.); in vivo proof-of-concept formulations

in oncology and hematology (po.), wound healing (top.), and

canine cancers (itu.); and early discovery targets in

infectious disease and tissue regeneration & repair.

Company Leadership

The board of directors and management team have

diverse and complementary experiences and a strong

collective track record of principled culture building,

decision-making, and business execution to accomplish

Provectus’s vision and mission.

* Notes: Routes of administration: itu. = intratumoral, top. = topical, po. = oral.

OTCQB: PVCT

OUR UNYIELDING RESOLVE

VISION

Transforming the way the healthcare industry treats

disease

MISSION

To innovate safe, effective, accessible, and affordable

immunotherapy medicines, while revolutionizing the

healthcare industry as we know it

Igniting the Embers of Hope

OTCQB: PVCT

THE SCIENCE BEHIND RBS

RBS MEDICAL SCIENCE: Platform Value Proposition

Safety

Broad-

spectrum

activity

Healing

capacity

Precise,

personalized &

potentially

permanent

immune response

Synergy with

standards of

care

Global accessibility

via affordability

Autolysis of Injected

Tumor Tissue

Intralesional Injection

DAMP &

Antigens Release,

DC Recruitment,

Antigen Uptake

T-Cell Activation

T-Cell Trafficking &

Checkpoint Blockade

Immune Killing of

Cancer Cells

INJECTABLE SOLID TUMOR ONCOLOGY: Mechanisms of Action

1. E.g., Keytruda® (pembrolizumab), Opdivo® (nivolumab), Yervoy® (ipilimumab), Yervoy+Opdivo, Bavencio® (avelumab), etc.

OTCQB: PVCT

GO TO MARKET STRATEGY

Provectus:

The only source of effectively pure,

regulatorily viable, commercially differentiated RBS API

Pharmaceutical Grade RBS:

ü Proprietary, patented, commercially scalable processes of

synthesizing the RBS molecule into a viable API

ü Established CMC specifications for API and drug product

manufacturing

ü Multi-year stability testing of multiple API and PV-10 drug

product lots

ü CMC data review and acceptance by numerous different

national drug regulatory agencies

Our RBS manufacturing processes employ QbD principles,

meet cGMP regulations, and follow ICH guidelines.

Provectus employs process controls to eliminate the formation of historical

impurities, avoid the introduction of hazardous impurities in uncontrolled

or unreported amounts, and prevent substantial lot-to-lot variability that

are all present in non-pharmaceutical grades of rose bengal.

Provectus’s Tr a d e m a r k for Our Processes of

Synthesizing the RBS Molecule into a Pharmaceutical API

* Notes: API = active pharmaceutical ingredient; CMC = chemistry, manufacturing, and control; QbD = quality by design; cGMP = current Good Manufacturing Practice; ICH = The International Council for

Harmonization of Technical Requirements for Pharmaceuticals for Human Use

1. CMC data reviews by U.S. FDA, Germany’s BfArM, Australia’s TGA under a clinical trial notification, France’s ANSM, Italy’s AIFA, Mexico’s COFEPRIS, and Argentina’s ANMAT for a pivotal Phase 3 cancer trial.

OTCQB: PVCT

IMMUNOTHERAPY TREATMENT

FOR CANCER

1. Source: World Health Organization

Provectus is a clinical-stage biotechnology company developing

immunotherapy treatments for cancer and many other diseases based

on a class of halogenated xanthene molecules.

Our flagship molecule is Rose Bengal Sodium, which we are

testing to treat injectable solid tumor cancers with our lead

intratumoral immunotherapy candidate PV-10.

Our network of devoted physician-scientists and researchers at major

U.S. and international medical institutions is working tirelessly to bring

RBS small molecule immunotherapy treatments to the world.

We invite you to follow our innovation, progress, and growth as we

execute on this exciting mission to change lives.

10 MILLION (est.)

People Die Annually from Cancer

OTCQB: PVCT

INJECTABLE SOLID TUMOR ONCOLOGY

Co-Lead Indication

• Pre-operative penile squamous cell carcinoma (SCC)

Penile SCC

• Monotherapy intratumoral PV-10

• SOC is penectomy

6-to-9-Patient, Single-Site, Phase 1 Trial

• Maximizes PV-10’s intrinsic advantages

• Rapid local response

• Tissue preservation pre-surgery

• Immunologic activation

Endpoints

• Safety and tolerability, index lesion measurement and photodocumentation, immune correlative

markers

* Notes: ORR = overall response; RECIST = response evaluation criteria in solid tumors;; AA = accelerated approval

FDA Clearance

Maximized PV-10

Treatment May Mitigate or

Eliminate Surgery

May Seek AA Based on

Phase 1 Trial Results

OTCQB: PVCT

INJECTABLE SOLID TUMOR ONCOLOGY

Co-Lead Indication

• FOLFIRNOX-refractory pancreatic ductal adenocarcinoma metastatic to the

liver

mPDAC

• Intratumoral PV-10 + systemic gemcitabine+nab-paclitaxel (GEM-PAC)

• 2

-line: Versus historical GEM-PAC; est. 7 months median OS

18-Patient, Single-Site, Dose Escalation Phase 1 Trial

• Proposed study design aligned with FDA initiative Project Optimus

• 3 dose levels (6 patients each) based on PV-10 tumor fill factor

Endpoints

• Safety and tolerability, PFS (RECIST), OS, and immune correlative markers

• First PET-CT scan (PERCIST) at 24 weeks (6 months) after initial PV-10

treatment

FDA Clearance via

Type C Meeting Request

Maximized PV-10 Dosing

Regimen May Substantially

Improve Patient Outcomes

* Notes: OS = overall survival; PFS = progression-free survival; RECIST = response evaluation criteria in solid tumors; PET-CT = positron emission tomography (PET)–computed tomography (CT);

PERCIST = positron emission tomography response criteria in solid tumors; AA = accelerated approval

1. Provectus Substack: Statistical modeling of PV-10 and chemotherapy for FOLFIRINOX-refractory pancreatic cancer metastatic to the liver (July 24, 2023)

May Seek AA Based on

Phase 1 Trial Results

OTCQB: PVCT

AI-ASSISTED CANCER MECHANISM ANALYSIS OF RBS

Hypothesis

• RBS acts through a multiplicity of anti-cancer mechanisms.

Methodology

• Conducted a systematic, GPT-4-assisted, review and analysis of 457 PubMed-indexed articles

mentioning “rose

bengal” and “cancer” from 1958 to 2026.

• Traced mechanistic consistency and therapeutic logic across independent studies, tumor types, and delivery

approaches, among other things.

Key Findings

• Identified numerous reproducible RBS mechanisms or approaches consistently observed across tumor types and

delivery methods.

• RBS is not target-specific but is environment- and system-responsive.

• High confidence level based on reproducibility, cross-validation across delivery platforms, immune activation

markers, and lack of contradictory findings, among other factors.

Conclusions

• RBS is best understood not as a traditional drug, but as a biological re-programmer that may potentially activate

both death and defense in the tumor setting.

• The molecule may trigger intrinsic, immunologically meaningful cell death while potentially awakening systemic

immune machinery.

• RBS’s potential versatility, safety, and reproducibility across models and modalities offer

compelling evidence for its potential widespread use for the oral treatment of solid tumor

and blood cancers.

1. PubMed comprises more than 38 million citations for biomedical literature from MEDLINE, life science journals, and online books. It is maintained by the United States National Library of

Medicine at the National Institutes of Health.

OTCQB: PVCT

Disease Administration Notes

Oncology itu.

Ophthalmology top.

Dermatology top.

Oncology po. / itu. pediatric

Hematology po.

Wound Healing top.

Animal Health itu.

Infectious Diseases tbd

Tissue Regeneration tbd

RBS MEDICAL SCIENCE PLATFORM

CLINICAL

STAGE

IN VIVO PROOF OF

CONCEPT

IN VITRO

PV-10: Stage III and IV melanoma; Cancers of the liver; Co-lead indications: penile SCC & mPDAC

PV-305: Infectious keratitis

(spun-out from Provectus as VisiRose, Inc.)

PH-10: Psoriasis and atopic dermatitis; skin inflammation

po.: Adult solid tumor cancers / itu.: Pediatric solid tumors

Pediatric and adult blood cancers, including leukemias

Full-thickness cutaneous wounds (e.g., surgical, burn, etc.)

Canine soft tissue sarcomas

Viruses, bacteria, fungi

* Notes: mPDAC = pancreatic ductal adenocarcinoma (PDAC) metastatic to the liver. Routes of administration: itu. = intratumoral, top. = topical, po. = oral, tbd = to be determined.

1. Clinical pilot study by Bascom Palmer Eye Institute; international randomized controlled trials for acanthamoeba and fungal (NCT05110001) and bacterial (NCT06271772) keratitis; clinical

treatment in India (LV Prasad Eye Institute and Aravind Eye Care System), Brazil (Universidade Federal de Sao Paulo), and Mexico (Instituto de Oftalmología)

THE FUTURE OF

EYE CARE

Rose Bengal &

Photodynamic

Therapy

Revolutionary Treatments for Infectious

Keratitis and Other Eye Diseases

INTRODUCING VISIROSE

Vision is humanity’s most treasured sense.

Yet for countless people worldwide, the scourge of eye

infection and disease has stolen this precious faculty of

sight, cloaking them in shadows, discomfort, and often

perpetual darkness.

VisiRose is pioneering a global revolution to protect and restore vision.

Through invention, science, and technology, VisiRose is committed to

reclaiming what has been lost, offering the transformative gift of

renewed sight.

VisiRose is a clinical-stage biotechnology company of the University of

Miami and Provectus Biopharmaceuticals, focused on commercializing

the Miller School of Medicine’s Bascom Palmer Eye Institute and its

Ophthalmic Biophysics Center’s innovative ocular research using

bioactive synthetic small molecule rose bengal.

VisiRose is transforming lives through the restoration of vision.

OTCQB: PVCT

LEADERSHIP TEAM

Dominic Rodrigues

President & Vice Chairman of the Board

• Management consulting and corporate development in

science & technology-driven industries

• Finance professor at University of Nevada, Las Vegas;

Venture capitalist at defense contractor SAIC; Currency

derivatives trader at Bank of Montreal; Project manager

and engineer at Jacques Whitford

• Holder of new Provectus patents

• Since 2017

Heather Raines, CPA

CFO

• Previously VP of Finance for BDry Waterproofing,

managed financial and accounting functions at AMETEK

(NYSE: AME)

• Tax analyst at Goody’s Family Clothing; Accounting

Manager at Siemens Medical Solutions USA, wholly owned

subsidiary of Siemens AG (NYSE: SI), and CTI Molecular

Imaging (Nasdaq: CTMI)

• Since 2018

Ed Pershing, CPA

CEO & Chairman of the Board

• Former CEO and co-founder of Pershing Yoakley &

Associates (PYA), top 20 healthcare consulting and top 100

accounting firm in U.S.

• Healthcare experience: turnaround/performance

improvement initiatives, long-range planning studies,

development of numerous hospital and medical office

projects, restructuring of healthcare organizations, liaison

between boards of directors and management teams,

mergers, acquisitions, divestitures, and leasing

arrangements

• Holder of new Provectus patents

• Since 2017

Eric Wachter, Ph.D.

CTO

• Co-founder of Photogen Technologies, Provectus’s

precursor company

• Previously senior research staff member with Oak Ridge

National Laboratory (ORNL) conducting research and

development of advanced nanosensor and remote sensor

technologies in environmental and biomedical sciences as

well as for defense and transportation applications

• Holder of more than 40 patents and several research

awards

• Since 2002

John Lacey, III, M.D.

Director

• Former Chief Medical Officer and Senior Vice

President of University Health System d/b/a University

of Tennessee Medical Center (UTMC); operated

internal medicine practice for 39 years

• Helped create Knoxville Area Project Access,

partnership with Knoxville Academy of Medicine and

providers to give primary and specialty health services

to uninsured and medically underserved

• Since 2018

Webster Bailey

Director

• Executive Director of Metro Drug Coalition

• 15-year career working in residential addiction

treatment center setting

• Winner of multiple awards and accolades for substance

abuse prevention initiatives

• Since 2020

OTCQB: PVCT

We employ open-source collaboration for basic, applied, and translational medical research, identifying and working with

expert physician-researchers and scientists in different disease areas who touch and treat patients every day, cross-

sharing molecular biochemical, mechanism, and other knowledge. Our curious, committed, and perseverant network in

the U.S. and internationally powers Provectus’s drug development endeavors. This is what sets us apart.

OUR COMPETITIVE ADVANTAGE

Open-Source Scientific Research Network

Supporting Proprietary Drug Development

OTCQB: PVCT

CAPITAL MARKETS SNAPSHOT

Ticker

PVCT

Exchange

OTCQB

Sector

Biotechnology

Market Cap

$24.80

million

-Week Range

0.054 - $0.12

Shares Outstanding

420.28 million

1. As of December 31, 2025.

Mailing Address

Provectus Biopharmaceuticals, Inc.

800 S. Gay St., Suite 1610

Knoxville, TN 37929 USA

+1 (866) 594-5999 / Fax: +1 (866) 998-0005

Investor Relations

investorrelations@pvct.com

+1 (866) 594-5999 x1

Media Relations

mediarelations@pvct.com

+1 (866) 594-5999 x4

Transfer Agent

(e.g., stockholder records, transfers, changes of address)

Broadridge Corporate Issuer Solutions, Inc.,

P.O. Box 1342, Brentwood, NY 11717 USA

shareholder@broadridge.com

+1 (800) 733-1121 / Fax: +1 (215) 553-5402

OTCQB: PVCT

WHY INVEST IN PROVECTUS

Highly experienced &

passionate management

focused on principled

culture building, decision-

making, and business

strategy execution

Clinical trials

demonstrating

viability of lead cancer

immunotherapy

candidate PV-10

Committed to developing

safe, effective, accessible

and affordable

immunotherapy drugs for

those afflicted with

cancer and other diseases

Open-source network of

physician-researchers,

scientists, and major

medical institutions

to alleviate high R&D

fixed costs

Corporate principles

of cure, accessibility,

accountability,

fiscal responsibility, and

shareholder value

OTCQB: PVCT

info@provectus.com

OTCQB: PVCT